ALK and non-small cell lung carcinoma: In support of the efficacy of homogenization therapy, a case study of a patient with ALK-rearranged non-small-cell lung cancer (NSCLC) has been described, where the authors postulated that cells exhibited unique, temporally restricted collateral sensitivities during adaptation to ALK inhibition (49, 91).